Triastek (Nanjing) Pharmaceutical Technology Co., Ltd. (“Triastek”) announced that it has entered into a Collaboration and License Agreement with Johnson & Johnson (J&J, NYSE: JNJ), combining J&J’s expertise in drug development with Triastek’s capabilities in 3D printing pharmaceutical technology and oral delivery of peptides and other therapeutic modalities to jointly develop novel oral medicines. Concurrently, Johnson & Johnson Innovation – JJDC, Inc., the corporate venture capital arm of Johnson & Johnson, has made a strategic equity investment in Triastek.
Deal Snapshot
| Item | Detail |
|---|---|
| Partners | Triastek (Nanjing) Pharmaceutical Technology / Johnson & Johnson (NYSE: JNJ) |
| Agreement Type | Collaboration and License Agreement |
| Strategic Investor | Johnson & Johnson Innovation – JJDC, Inc. (equity investment) |
| Therapeutic Focus | Novel oral medicines (peptides and other modalities) |
| Core Technology | 3D printing pharmaceutical technology / oral peptide delivery |
| Announcement Date | 09 Oct 2026 |
Technology Platform Profile
- MED&SSE Platform: Triastek’s proprietary Melt Extrusion Deposition plus Semi‑Solid Extrusion technology — a 3D printing pharmaceutical manufacturing process that enables precise control over tablet architecture and drug release profiles.
- 3DμS‑OM Platform: Triastek’s oral medicine platform designed to address delivery challenges in oral drug development, particularly for peptides and complex therapeutic modalities traditionally limited to injectable routes.
- Manufacturing Advantages: The platform combines room‑temperature and low‑shear manufacturing processes with advanced tablet structure design, preserving the stability of heat‑sensitive and shear‑sensitive active pharmaceutical ingredients (APIs).
- Oral Peptide Delivery: A key capability enabling the conversion of injectable biologics and peptides into patient‑friendly oral dosage forms — one of the most persistent challenges in modern pharmaceutical development.
Strategic Rationale & Market Context
- Oral Peptide Opportunity: The pharmaceutical industry has long pursued oral alternatives to injectable peptides and biologics, which currently dominate treatment regimens in oncology, metabolic diseases, and autoimmune disorders. Successful oral delivery could dramatically improve patient compliance and reduce administration costs.
- J&J’s Pipeline Strategy: The collaboration positions Johnson & Johnson to leverage advanced formulation and manufacturing technologies to accelerate the oral development of pipeline candidates across its therapeutic portfolio, reducing reliance on traditional formulation approaches.
- 3D Printing in Pharma: 3D printing pharmaceutical technology is an emerging manufacturing paradigm that enables personalized dosing, complex release profiles, and multi‑layer tablet designs not achievable through conventional tableting — attracting increasing interest from major pharmaceutical companies.
- JJDC Investment Signal: The simultaneous equity investment by JJDC underscores the strategic importance Johnson & Johnson places on the partnership and signals confidence in Triastek’s technology platform for long‑term value creation.
Forward‑Looking Outlook
- Development Pipeline: Specific drug candidates under the collaboration and associated development timelines were not disclosed at the time of announcement.
- Commercial Terms: Financial details of the license agreement, including upfront payments, milestones, and royalty structures, were not disclosed.
- Investment Amount: The size of JJDC’s equity investment in Triastek was not disclosed.
- Next Steps: The parties are expected to advance joint development programs leveraging Triastek’s 3D printing platform and J&J’s drug development capabilities, with further updates anticipated as programs progress.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding the collaboration between Triastek and Johnson & Johnson, including the expected development of novel oral medicines, the strategic equity investment by JJDC, and the potential of 3D printing pharmaceutical technology. Actual results may differ due to risks including drug development outcomes, regulatory pathways, technology scale‑up challenges, and competitive dynamics in advanced pharmaceutical manufacturing.-Fineline Info & Tech
